Telomir Pharmaceuticals, Inc.
TELO
$4.55
-$0.48-9.54%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 201.37% | 677.72% | 15.95% | 2,510.33% | 8,826.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 169.37% | 529.45% | 3.38% | 296.79% | 121.43% |
| Operating Income | -169.37% | -529.45% | -3.38% | -296.79% | -121.43% |
| Income Before Tax | 68.93% | -250.07% | 6.54% | -1,195.22% | -1,814.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 68.93% | -250.07% | 6.54% | -1,195.22% | -1,814.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.93% | -250.07% | 6.54% | -1,195.22% | -1,814.84% |
| EBIT | -169.37% | -529.45% | -3.38% | -296.79% | -121.43% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 71.62% | -220.09% | 14.51% | -1,151.11% | -1,791.21% |
| Normalized Basic EPS | -44.10% | -220.25% | 14.53% | -1,157.14% | -275.22% |
| EPS Diluted | 71.62% | -220.09% | 14.51% | -1,151.11% | -1,791.21% |
| Normalized Diluted EPS | -44.10% | -220.25% | 14.53% | -1,157.14% | -275.22% |
| Average Basic Shares Outstanding | 9.46% | 9.27% | 9.27% | 3.25% | 1.00% |
| Average Diluted Shares Outstanding | 9.46% | 9.27% | 9.27% | 3.25% | 1.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
